Positron seeing substantial accumulation. May pierce resistance levels. Print E-mail
By M.E.Garza   
Thursday, 17 June 2010 17:32

Positron Corporation (OTCBB:POSC), a leader in molecular imaging and solutions specializing in the field of Nuclear Cardiology has just released a report over the news wires highlighting some of the company's key points and developments.

The stock has been seeing quite a bit of accumulation since shares broke the $.10 support level a few days ago and Thursday, shares closed up 11.6% at $.125. We believe the stock will climb higher pending announcements and long awaited official revelation of a key relationship or two with big-cap firms in the biotech imaging space. Those relationships and developments, as they are announced, may signal what investors have been waiting for: the validation and start of next level of commercialization and deployment activities surrounding the company's Molecular Imaging Devices and Radiopharmaceutical Products.

Here is a marked up technical analysis chart of the company:

Here is a synopsis of some of the key points which were announced today by the company:

Positron’s core focus is to leverage their unique technologies and competencies to offer an industry unique total customer solution which includes low cost molecular imaging devices and service, disease specific software, radiopharmaceutical distribution delivery systems, and imaging agents for Nuclear Cardiology. Positron's strategy is to utilize all of its innovative equipment to maximize market share within the molecular imaging market.


Positron’s molecular imaging device segment includes the Attrius™, a Positron Emission Tomography (PET) imaging device that is the only cardiac optimized dedicated PET device in the world.

Positron’s Attrius™ PET scanner, with its robust software package, will help physicians provide a more accurate diagnosis for patients, the potential to reduce unnecessary downstream procedures and allow for higher reimbursement compared to SPECT. Positron also offers a Single Photon Emission Computed Tomography (SPECT) camera, the Pulse™, is one of the leading SPECT imaging devices in the industry with over 150 units sold.

Positron’s radiopharmaceutical segment includes the Nuclear Pharm-Assist® line of equipment, the world’s first robotic system for the distribution of radiopharmaceutical agents for PET and SPECT imaging devices. The Nuclear Pharm-Assist® automates the preparation and dispensing of radiopharmaceuticals and acts as a “virtual pharmacy” located on site at the nuclear pharmacy or physician’s office to dispense the radiopharmaceutical as a patient specific dose. The Nuclear Pharm-Assist® makes the distribution of the radiopharmaceutical economical, efficient and regulatory compliant.

The market at the present time is 7,000+ cardiac imaging opportunities that are all ideal candidates for the evolution of PET imaging and the direct distribution of radiopharmaceuticals.

Positron estimates the market for dedicated cardiac PET scanners in the United States to be above $3 billion in device sales over the next 5 years. According to Bio-Tech Systems, a research firm that covers the diagnostic imaging market, nuclear cardiology radiopharmaceutical sales of $1.29 billion in 2007 will increase to $2.10 billion by 2014. In a study conducted by Frost & Sullivan, the medical imaging consumables market is expected to grow at a compound annual rate of 14 percent, driven by an aging baby boomer population & increased life expectancy this rise is increasing more than twice as fast as the total population.




  • Positron’s Attrius™ is the only FDA approved standalone dedicated cardiac PET scanner on the market optimized for cardiology. All major PET manufacturers have discontinued manufacturing of PET only systems, offering only PET/CT instead. The addition of an expensive CT provides certain advantages for oncology imaging applications however is not necessary for cardiac imaging procedures. PET/CT has also been shown to have higher radiation exposure levels to patients compared to dedicated PET. Positron intends to fill the market niche with its Attrius™ Cardiac PET.
  • The Attrius™ includes a robust, cardiac specific, imaging software package designed to ensure effortless interpretation for today’s most challenging clinical cases for nuclear cardiologists who value high quality PET imagery at an affordable price. The system is designed to provide concurrent acquisition, reconstruction, image processing and display, as well as other functions such as data archiving, without interference.
  • Positron’s Attrius™ named “Most Innovative Medical Device of 2010 Award” by the industry leading research firm, Frost and Sullivan.
  • A twofold increase in reimbursement of cardiac PET applications by CMS in the last 3 years, with a 25% increase in 2010 alone (while SPECT cardiac imaging reimbursement has been decreased by 20%), which has greatly increased interest in cardiac PET applications. These dramatic changes further validates that PET is the future of nuclear cardiology and that there is an industry wide urgency in the evolution to PET from SPECT.
  • CMS (Medicare) has approved PET as a first-line cardiac diagnostic test. The medical imaging industry has regarded PET as the best imaging modality;
  • With recent increased reimbursement and challenging medical budgets, it further validates PET as the most efficient, economical and provides the best medicine choice for physicians. PET is the next SPECT which currently is 99% of the cardiac imaging market. As PET replaces a large percentage of SPECT systems, this would represent a total cardiac PET device market of approximately $3 billion dollars.


  • Positron’s revolutionary “virtual pharmacy” solutions, Nuclear Pharm-Assist® allows placing pharmaceutical dose delivery systems into nuclear pharmacy’s and/or the physician’s offices and provides unprecedented “Unit Dose” flexibility to imaging providers at the touch of a button, 24/7. The systems meets the requirements of the United States Pharmacopeia Chapter 797 compounding regulations as a compounding aseptic containment isolator (CACI) and provides the ISO Class 5 environment necessary for USP-797 compliance as well as automating the basic radiopharmaceutical compounding procedures. Most Nuclear medicine facilities and nuclear pharmacies are underprepared and have to make considerable investments to meet requirements of USP-797 which are in force since June 2008. Nuclear Pharm-Assist® provides Automation, Shielding, Compliance, Patient management, Costs & Margins.
  • Positron has an agreement with an industry leading partner for the development and distribution of cardiac radiopharmaceuticals. This partnership represents thousands of potential customers throughout the US and world. Each distributed Nuclear Pharm-Assist® system represents approximately $250,000 in annual sales. This pending rollout will be the beginning of Positron being a leader in radiopharmaceutical distribution.
  • Radiopharmaceuticals, Sestimibi and Rubidium, are now available as a generic pharmaceutical and are set to become commercially available with a number of pharma companies. Lower cost and increased suppliers will help grow our segment of the industry. Positron is working with the largest companies in this field.
  • A number of the largest radiopharmaceutical companies are developing single dose cardiac PET imaging agents. This fact alone further validates that PET is the most valuable first line cardiac imaging modality. New cardiac PET specific radiopharmaceuticals will further increase the demand for Positron’s Attrius™ Cardiac PET system, the only new PET only device available today. Positron patient studies demonstrate that the Attrius™ PET scanner meets the performance requirements for all PET myocardial perfusion imaging tracers.
  • Positron has a number of patents and patents pending. Most recently has received a patent on its Tech-Assist™, FDG injection shielding device.
  • Molybdenum (SPECT drug) shortages have increased the value if not necessity of its model of drug distribution. This drug shortage awakens the industry to the rationale and relevance of the Positron Nuclear Pharm-Assist® line.

Positron will explore additional strategic interests to the Company that advance PET imaging systems and radiopharmaceutical distribution. Positron will continue to evaluate all organic and strategic partnership opportunities and is prepared to engage in more robust business development opportunities that meet its objectives as being the leader in nuclear cardiology. These opportunities could be in a variety of areas, such as partnerships with cardiologist practices, radiopharmaceutical distribution, radiopharmaceutical manufacturing and partnerships with companies that serve the molecular imaging industry. As Positron executes its core focus and strategic interest areas, additional areas may be pursued.

Disclosure: No positions

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus